03.27.23 -- Tackling Safety Issues Of Adjuvanted Vaccines

The extremely high variability in the individual media components’ concentrations suggests little similarity across different commercial sources of SOB media.

While this critical decision is not novel for the life sciences, the factors impacting it change year to year and have become increasingly complex.

Impurities from IVT can induce undesired immune responses and negatively impact translation efficiency. Discover the pros and cons of each option for mRNA purification, challenges, strategies, and more.

Specializing in oncology, anti-infective, and complex formulations, the facility provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

Ajinomoto Bio-Pharma's Dr. Bert Metten fields questions on continuous flow, including scale-up parameters, modeling approaches, reactor design, and reaction optimization.

The drug development journey is long, expensive, resource straining, and risky. Discover how to maximize the value of early-phase material and match your development path to your IND milestones.

They are many environments that may be contaminated with bacterial endotoxins, because Gram-negative bacteria are characterized by their great level of ubiquity.

Having a secondary supplier in place for the manufacturing and packaging of lifesaving critical medicines should be an essential part of your strategy in terms of patient health.

Get a behind-the-scenes look at efforts to develop a COVID-19 vaccine, as it happened, and the collaborative mindset that brought it here as quickly and safely as possible.

Review an evaluation of the OsmoTECH XT (freezing point) and Vapro 5600 (vapor pressure) osmometers as a means of measuring concentrated protein formulations.

Since physical structure and biological activity are directly linked, controlling the physical form of a compound is paramount to a final drug product’s quality and effectiveness.